{"title":"NCAPG2 promotes the proliferation, metastasis and resistance to nab-paclitaxel in gastric adenocarcinoma cells.","authors":"Jia Xu, Xiaoyuan Liu, Zebo Huang, Ying Zhang, Xia Li, Dongyan Cai","doi":"10.1080/1120009X.2025.2498230","DOIUrl":null,"url":null,"abstract":"<p><p>Gastric adenocarcinoma is one of the most common cancers in the world. The purpose of this study was to investigate the role of non-smooth muscle cell aggregation protein II complex G2 subunit (NCAPG2) in gastric cancer cells. Cell growth, proliferation, migration, invasion and albumin-bound paclitaxel resistance were detected by cell counting kit-8, flow cytometry, Transwell chamber and nude mouse xenograft model. Western blot was used to detect the expression of NCAPG2, STAT3 and NF-κB signaling pathways. The expression of NCAPG2 was significantly up-regulated in gastric adenocarcinoma cells. Knockdown of NCAPG2 inhibited cell proliferation, migration and invasion, and inhibited tumor growth. In addition, knockdown of NCAPG2 reduced the resistance of gastric adenocarcinoma cells to albumin-bound paclitaxel and down-regulated STAT3 and NF-κB signaling pathways. In summary, NCAPG2 plays an important role in the malignant progression of gastric adenocarcinoma and is involved in the resistance to albumin-bound paclitaxel.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2025.2498230","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Gastric adenocarcinoma is one of the most common cancers in the world. The purpose of this study was to investigate the role of non-smooth muscle cell aggregation protein II complex G2 subunit (NCAPG2) in gastric cancer cells. Cell growth, proliferation, migration, invasion and albumin-bound paclitaxel resistance were detected by cell counting kit-8, flow cytometry, Transwell chamber and nude mouse xenograft model. Western blot was used to detect the expression of NCAPG2, STAT3 and NF-κB signaling pathways. The expression of NCAPG2 was significantly up-regulated in gastric adenocarcinoma cells. Knockdown of NCAPG2 inhibited cell proliferation, migration and invasion, and inhibited tumor growth. In addition, knockdown of NCAPG2 reduced the resistance of gastric adenocarcinoma cells to albumin-bound paclitaxel and down-regulated STAT3 and NF-κB signaling pathways. In summary, NCAPG2 plays an important role in the malignant progression of gastric adenocarcinoma and is involved in the resistance to albumin-bound paclitaxel.
期刊介绍:
The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy.
The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs.
Specific areas of focus include, but are not limited to:
· Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents;
· Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy;
· Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents;
· The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs;
· Drug interactions in single or combined applications;
· Drug resistance to antimicrobial and anticancer drugs;
· Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research;
· Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs;
· Pharmacogenetics and pharmacogenomics;
· Precision medicine in infectious disease therapy and in cancer therapy;
· Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.